Selective BH3 mimetics synergize with BET inhibition to induce mitochondrial apoptosis in rhabdomyosarcoma cells

BH3 mimetics are promising novel anticancer therapeutics. By selectively inhibiting BCL-2, BCL-x(L), or MCL-1 (i.e. ABT-199, A-1331852, S63845) they shift the balance of pro- and anti-apoptotic proteins in favor of apoptosis. As Bromodomain and Extra Terminal (BET) protein inhibitors promote pro-apo...

Descripción completa

Detalles Bibliográficos
Autores principales: Erdogdu, Ufuk, Dolgikh, Nadezda, Laszig, Stephanie, Särchen, Vinzenz, Meister, Michael T., Wanior, Marek, Knapp, Stefan, Boedicker, Cathinka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718565/
https://www.ncbi.nlm.nih.gov/pubmed/34959030
http://dx.doi.org/10.1016/j.neo.2021.11.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718565/
https://www.ncbi.nlm.nih.gov/pubmed/34959030
http://dx.doi.org/10.1016/j.neo.2021.11.012

Ejemplares similares